Prelude Therapeutics Incorporated Share Price
PRLDPrelude Therapeutics Incorporated Stock Performance
Open $4.28 | Prev. Close $4.28 | Circuit Range N/A |
Day Range $4.20 - $4.47 | Year Range $0.76 - $5.54 | Volume 8,156 |
Average Traded $4.38 |
Prelude Therapeutics Incorporated Share Price Chart
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Incorporated Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-May-26 | $4.28 | $4.50 | +0.00% |
20-May-26 | $4.28 | $4.50 | +3.56% |
18-May-26 | $4.37 | $4.35 | -3.76% |
15-May-26 | $4.26 | $4.52 | +0.56% |
14-May-26 | $4.50 | $4.50 | -3.75% |
13-May-26 | $4.67 | $4.67 | +0.65% |
12-May-26 | $4.90 | $4.64 | -3.33% |